GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CTI BioPharma Corp (FRA:CEPS) » Definitions » Common Stock

CTI BioPharma (FRA:CEPS) Common Stock : €0.12 Mil (As of Mar. 2023)


View and export this data going back to 2007. Start your Free Trial

What is CTI BioPharma Common Stock?

CTI BioPharma's quarterly common stock declined from Sep. 2022 (€0.13 Mil) to Dec. 2022 (€0.12 Mil) and declined from Dec. 2022 (€0.12 Mil) to Mar. 2023 (€0.12 Mil).

CTI BioPharma's annual common stock increased from Dec. 2020 (€0.06 Mil) to Dec. 2021 (€0.09 Mil) and increased from Dec. 2021 (€0.09 Mil) to Dec. 2022 (€0.12 Mil).


CTI BioPharma Common Stock Historical Data

The historical data trend for CTI BioPharma's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CTI BioPharma Common Stock Chart

CTI BioPharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.05 0.06 0.09 0.12

CTI BioPharma Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.09 0.11 0.13 0.12 0.12

CTI BioPharma Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


CTI BioPharma (FRA:CEPS) Business Description

Traded in Other Exchanges
N/A
Address
3101 Western Avenue, Suite 800, Seattle, WA, USA, 98121
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.

CTI BioPharma (FRA:CEPS) Headlines

No Headlines